Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | CD44 | P16070 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CETP | P11597 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 2/20 | 0.31 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9058839 | 0.86 | HTR2C (0.30) | HTR2C | |
| SCHEMBL423294 | 0.83 | ADORA2A (0.35) | HTR2CCD44CYP1A2CYP2A6CA1 | |
| SCHEMBL14547572 | 0.82 | HTR2C (0.32) | HTR2CCD44CYP1A2CYP2A6CA1 | |
| SCHEMBL21937643 | 0.80 | HTR2C (0.31) | HTR2CCD44CYP1A2CYP2A6 | |
| SCHEMBL14747859 | 0.80 | HTR2C (0.31) | HTR2CCD44CYP1A2CYP2A6 | |
| SCHEMBL10522329 | 0.77 | ALDH1A1 (0.46) | HTR2CCD44CYP1A2CYP2A6CA1 | |
| SCHEMBL26304580 | 0.77 | HPGD (0.36) | HTR2CCD44CYP1A2CYP2A6CA1 | |
| SCHEMBL8958899 | 0.75 | CETP (0.31) | CETP | |
| SCHEMBL21009663 | 0.75 | MAP3K14 (0.34) | HTR2CCD44CYP1A2CYP2A6CA1 | |
| SCHEMBL418853 | 0.75 | CETP (0.33) | CD44ALDH1A1CETPTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3429355-B1 | SUBSTITUTED SULFONYLAMIDE FOR COMBATING ANIMAL PESTS | BAYER CROPSCIENCE AG (DE) | 2020-02-05 | — | — | EP | disclosed |
| WO-2017157735-A1 | SUBSTITUTED SULFONYL AMIDES FOR CONTROLLING ANIMAL PESTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-09-21 | — | — | WO | disclosed |
| US-9115065-B2 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with Arenaviruses | Kineta, Inc. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9067873-B2 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | Kineta Four, LLC (US) | 2015-06-30 | — | — | US | disclosed |
| US-20140378681-A1 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS,PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES | SIGA TECHNOLOGIES INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140275037-A1 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES | SIGA TECHNOLOGIES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8664274-B2 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena viruses | SIGA TECHNOLOGIES, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-8658697-B2 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | SIGA TECHNOLOGIES, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8642596-B2 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena viruses | SIGA TECHNOLOGIES, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130261087-A1 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENA VIRUSES | SIGA TECHNOLOGIES INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-04-17 | — | — | US | disclosed |
| US-20070287698-A1 | Tetrahydrobenzo(D)Azepin-2-One Derivatives and the Use Thereof for Treating Cardiovascular Diseases | BAYER HEALTHCARE AG (DE) | 2007-12-13 | — | — | US | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-02-22 | — | — | US | disclosed |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-02-22 | — | — | US | disclosed |
| WO-2005007621-A2 | UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| WO-2002012236-A1 | SUBSTITUTED TRIAZOLOPYRID(AZ)INES AS PLANT TREATMENT AGENTS (HERBICIDES) | BAYER CROPSCIENCE AG (DE) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275037-A1 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES | GBA1, GK, GCK | HTR2C 4150/4885CD44 4212/4885CYP1A2 4380/4885 |
| US-20070287698-A1 | Tetrahydrobenzo(D)Azepin-2-One Derivatives and the Use Thereof for Treating Cardiovascular Diseases | APOB, PCSK9, BDKRB1 | HTR2C 2143/4885CD44 4436/4885CYP1A2 763/4885 |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | NAT1, EPX, HRH2 | HTR2C 994/4885CD44 793/4885CYP1A2 631/4885 |
| US-20140378681-A1 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS,PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES | GBA1, GK, GCK | HTR2C 4150/4885CD44 4212/4885CYP1A2 4380/4885 |
| US-20130261087-A1 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENA VIRUSES | SORD, GBA1, GK | HTR2C 4201/4885CD44 3344/4885CYP1A2 4716/4885 |
| US-20070185110-A1 | Antiallergic agents | NAT1, EPX, AHR | HTR2C 942/4885CD44 818/4885CYP1A2 576/4885 |
| US-20070185059-A1 | Antiallergic agents | NAT1, EPX, AHR | HTR2C 936/4885CD44 844/4885CYP1A2 589/4885 |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | TYR, XDH, XPA | HTR2C 2758/4885CD44 1390/4885CYP1A2 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.